Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Net Income (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Net Income for 14 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 42.44% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 103.3% increase, with the full-year FY2025 number at $17.4 million, up 103.3% from a year prior.
  • Net Income was $4.1 million for Q4 2025 at Niagen Bioscience, down from $4.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $7.2 million in Q4 2024 to a low of -$8.9 million in Q3 2021.
  • A 5-year average of -$1.2 million and a median of -$1.2 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 111.06% in 2021, then surged 24160.0% in 2025.
  • Niagen Bioscience's Net Income stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114000.0 in 2023, then soared by 6197.37% to $7.2 million in 2024, then crashed by 42.44% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Net Income are $4.1 million (Q4 2025), $4.6 million (Q3 2025), and $3.6 million (Q2 2025).